Edinburgh based biotech Lentitek has secured an equity investment of £725,000 from new and existing investors led by Equity Gap to accelerate commercialisation of its technology which improves manufacturability and quality of cell & gene therapies. This most recent investment follows a breakthrough year for the company in which it transitioned from R&D to revenue-generating, with several significant deals signed and much more in the pipeline. Interest in Lentitek’s technology has been driven by next generation in vivo CAR-T treatments moving from lab to clinic, an application in which quality is particularly critical.
Read more HERE.
